251 related articles for article (PubMed ID: 30286855)
1. 1-Year Clinical Outcomes of All-Comer Patients Treated With the Dual-Therapy COMBO Stent: Primary Results of the COMBO Collaboration.
de Winter RJ; Chandrasekhar J; Kalkman DN; Aquino MB; Woudstra P; Beijk MA; Sartori S; Baber U; Tijssen JG; Koch KT; Dangas GD; Colombo A; Mehran R; ;
JACC Cardiovasc Interv; 2018 Oct; 11(19):1969-1978. PubMed ID: 30286855
[TBL] [Abstract][Full Text] [Related]
2. 1-Year Results of the REMEDEE Registry: Clinical Outcomes After Deployment of the Abluminal Sirolimus-Coated Bioengineered (Combo) Stent in a Multicenter, Prospective All-Comers Registry.
Woudstra P; Kalkman DN; den Heijer P; Menown IB; Erglis A; Suryapranata H; Arkenbout KE; Iñiguez A; van 't Hof AW; Muller P; Tijssen JG; de Winter RJ
JACC Cardiovasc Interv; 2016 Jun; 9(11):1127-34. PubMed ID: 27209254
[TBL] [Abstract][Full Text] [Related]
3. 1-Year Clinical Outcomes of All Comers Treated With 2 Bioresorbable Polymer-Coated Sirolimus-Eluting Stents: Propensity Score-Matched Comparison of the COMBO and Ultrathin-Strut Orsiro Stents.
Chandrasekhar J; Kok MM; Kalkman DN; Aquino MB; Zocca P; Woudstra P; Beijk MA; Kerkmeijer LS; Sartori S; Baber U; Tijssen JG; Koch KT; Dangas GD; Colombo A; Pocock S; von Birgelen C; Mehran R; de Winter RJ;
JACC Cardiovasc Interv; 2020 Apr; 13(7):820-830. PubMed ID: 32273094
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of the COMBO bio-engineered stent in an all-comer PCI cohort: 1-Year final clinical outcomes from the MASCOT post-marketing registry.
Colombo A; Chandrasekhar J; Aquino M; Ong TK; Sartori S; Baber U; Lee M; Iniguez A; Hajek P; Borisov B; Atzev B; Den Heijer P; Coufal Z; Hudec M; Mates M; Snyder C; Moalem K; Morrell D; Elmore F; Rowland S; Mehran R;
Int J Cardiol; 2019 May; 283():67-72. PubMed ID: 30826192
[TBL] [Abstract][Full Text] [Related]
5. Three-year clinical outcomes after dual-therapy COMBO stent placement: Insights from the REMEDEE registry.
Kalkman DN; Kerkmeijer LS; Woudstra P; Menown IBA; Suryapranata H; den Heijer P; Iñiguez A; van 't Hof AWJ; Erglis A; Arkenbout KE; Muller P; Koch KT; Tijssen JG; Beijk MAM; de Winter RJ
Catheter Cardiovasc Interv; 2019 Sep; 94(3):342-347. PubMed ID: 30565371
[TBL] [Abstract][Full Text] [Related]
6. Clinical Outcomes of the Dual-Therapy CD34 Antibody-Covered Sirolimus-Eluting Stent Versus Standard Drug-Eluting Coronary Stents: A Meta-Analysis.
Ndunda P; Vindhyal MR; Muutu T; Fanari Z
Cardiovasc Revasc Med; 2020 Feb; 21(2):213-221. PubMed ID: 31147259
[TBL] [Abstract][Full Text] [Related]
7. The REMEDEE trial: 5-Year results on a novel combined sirolimus-eluting and endothelial progenitor cells capturing stent.
Haude M; Lee SWL; Worthley SG; Silber S; Verheye S; Rosli MA; Botelho R; Sim KH; Abizaid A; Mehran R;
Catheter Cardiovasc Interv; 2020 May; 95(6):1076-1084. PubMed ID: 31489742
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent for the treatment of de novo coronary lesions: Final five-year results of the patient-level pooled analysis from the TARGET I and TARGET II trials.
Li C; Guan C; Zhang R; Yang Y; Ma C; Li H; Chen S; Han Y; Xu B; Gao R;
Catheter Cardiovasc Interv; 2019 Feb; 93(S1):818-824. PubMed ID: 30565397
[TBL] [Abstract][Full Text] [Related]
9. One-year clinical results of the NANO registry: A multicenter, prospective all-comers registry study in patients receiving implantation of a polymer-free sirolimus-eluting stent.
Liu Y; Zhang Y; Li Y; Qi T; Pan D; Wang H; Liu C; Ma D; Fang Z; Zhang R; Mou F; Tao L;
Catheter Cardiovasc Interv; 2020 Feb; 95 Suppl 1():658-664. PubMed ID: 31961057
[TBL] [Abstract][Full Text] [Related]
10. The REMEDEE trial: a randomized comparison of a combination sirolimus-eluting endothelial progenitor cell capture stent with a paclitaxel-eluting stent.
Haude M; Lee SW; Worthley SG; Silber S; Verheye S; Erbs S; Rosli MA; Botelho R; Meredith I; Sim KH; Stella PR; Tan HC; Whitbourn R; Thambar S; Abizaid A; Koh TH; Den Heijer P; Parise H; Cristea E; Maehara A; Mehran R
JACC Cardiovasc Interv; 2013 Apr; 6(4):334-43. PubMed ID: 23523459
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent for the treatment of de novo coronary lesions: two-year results from a prospective patient-level pooled analysis of TARGET trials.
Gao Z; Zhang R; Xu B; Yang Y; Ma C; Li H; Chen S; Han Y; Yuan Z; Lansky AJ; Guan C; Leon MB; Gao R;
Catheter Cardiovasc Interv; 2015 Mar; 85 Suppl 1():734-43. PubMed ID: 25678281
[TBL] [Abstract][Full Text] [Related]
12. Early discontinuation of dual antiplatelet therapy in patients treated with the bio-engineered pro-healing sirolimus-eluting (COMBO) stent.
Kalkman DN; Woudstra P; Menown IBA; Tijssen JG; Beijk MAM; de Winter RJ;
Cardiovasc Revasc Med; 2018; 19(3 Pt B):373-375. PubMed ID: 29277288
[TBL] [Abstract][Full Text] [Related]
13. Clinical Outcomes One Year and Beyond After Combination Sirolimus-Eluting Endothelial Progenitor Cell Capture Stenting During Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction.
Sim HW; Thong EH; Tan HC; Low AF; Lee CH; Chan MY; Tay EL; Loh PH; Chan KH; Loh JP
Cardiovasc Revasc Med; 2019 Sep; 20(9):739-743. PubMed ID: 30442536
[TBL] [Abstract][Full Text] [Related]
14. One-year clinical outcome of biodegradable polymer sirolimus-eluting stent in diabetic patients: Insight from the ULISSE registry (ULtimaster Italian multicenter all comerS Stent rEgistry).
Beneduce A; Ferrante G; Ielasi A; Pivato CA; Chiarito M; Cappelletti A; Baldetti L; Magni V; Prati E; Falcone S; Pierri A; De Martini S; Montorfano M; Parisi R; Rutigliano D; Locuratolo N; Anzuini A; Tespili M; Margonato A; Benassi A; Briguori C; Reimers B; Fabbiocchi F; Bartorelli A; Colombo A; Godino C
Catheter Cardiovasc Interv; 2020 Aug; 96(2):255-265. PubMed ID: 31905259
[TBL] [Abstract][Full Text] [Related]
15. 2-Year Clinical Outcomes of an Abluminal Groove-Filled Biodegradable-Polymer Sirolimus-Eluting Stent Compared With a Durable-Polymer Everolimus-Eluting Stent.
Xu B; Saito Y; Baumbach A; Kelbæk H; van Royen N; Zheng M; Morel MA; Knaapen P; Slagboom T; Johnson TW; Vlachojannis G; Arkenbout KE; Holmvang L; Janssens L; Ochala A; Brugaletta S; Naber CK; Anderson R; Rittger H; Berti S; Barbato E; Toth GG; Maillard L; Valina C; Buszman P; Thiele H; Schächinger V; Lansky A; Wijns W;
JACC Cardiovasc Interv; 2019 Sep; 12(17):1679-1687. PubMed ID: 31129092
[TBL] [Abstract][Full Text] [Related]
16. 1-year results after PCI with the COMBO stent in all-comers in Asia versus Europe: Geographical insights from the COMBO collaboration.
Chandrasekhar J; Kalkman DN; Aquino MB; Sartori S; Hájek P; Atzev B; Hudec M; Ong TK; Mates M; Borisov B; Warda HM; den Heijer P; Wojcik J; Iñiguez A; Coufal Z; Khashaba A; Schee A; Munawar M; Gerber RT; Yan BP; Tejedor P; Kala P; Liew HB; Lee M; Baber U; Vogel B; Dangas GD; Colombo A; de Winter RJ; Mehran R; ;
Int J Cardiol; 2020 May; 307():17-23. PubMed ID: 32111358
[TBL] [Abstract][Full Text] [Related]
17. Randomized Comparison of a Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent With a Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention: The SORT OUT VII Trial.
Jensen LO; Thayssen P; Maeng M; Ravkilde J; Krusell LR; Raungaard B; Junker A; Terkelsen CJ; Veien KT; Villadsen AB; Kaltoft A; Tilsted HH; Hansen KN; Aaroe J; Kristensen SD; Hansen HS; Jensen SE; Madsen M; Bøtker HE; Berencsi K; Lassen JF; Christiansen EH
Circ Cardiovasc Interv; 2016 Jul; 9(7):. PubMed ID: 27412869
[TBL] [Abstract][Full Text] [Related]
18. The REMEDEE-OCT Study: An Evaluation of the Bioengineered COMBO Dual-Therapy CD34 Antibody-Covered Sirolimus-Eluting Coronary Stent Compared With a Cobalt-Chromium Everolimus-Eluting Stent in Patients With Acute Coronary Syndromes: Insights From Optical Coherence Tomography Imaging Analysis.
Jaguszewski M; Aloysius R; Wang W; Bezerra HG; Hill J; De Winter RJ; Karjalainen PP; Verheye S; Wijns W; Lüscher TF; Joner M; Costa M; Landmesser U
JACC Cardiovasc Interv; 2017 Mar; 10(5):489-499. PubMed ID: 28279316
[TBL] [Abstract][Full Text] [Related]
19. Randomized clinical comparison of the dual-therapy CD34 antibody-covered sirolimus-eluting Combo stent with the sirolimus-eluting Orsiro stent in patients treated with percutaneous coronary intervention: Rationale and study design of the Scandinavian Organization for Randomized Trials with Clinical Outcome (SORT OUT) X trial.
Jakobsen L; Christiansen EH; Maeng M; Kristensen SD; Bøtker HE; Terkelsen CJ; Madsen M; Raungaard B; Jensen SE; Christensen MK; Hansen HS; Jensen LO
Am Heart J; 2018 Aug; 202():49-53. PubMed ID: 29807307
[TBL] [Abstract][Full Text] [Related]
20. Biodegradable Polymer Biolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With Coronary Artery Disease: Final 5-Year Report From the COMPARE II Trial (Abluminal Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent).
Vlachojannis GJ; Smits PC; Hofma SH; Togni M; Vázquez N; Valdés M; Voudris V; Slagboom T; Goy JJ; den Heijer P; van der Ent M
JACC Cardiovasc Interv; 2017 Jun; 10(12):1215-1221. PubMed ID: 28579236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
